Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome

Pak J Pharm Sci. 2016 Nov;29(6):2103-2104.

Abstract

Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established. A total 60 patients with ACS were divided into three groups; receiving aspirin, clopidogrel and aspirin-clopidogrel combination. For determination of renal function, serum BUN, creatinine, uric acid, uric acid clearance and GFR were estimated for four months. The study showed that there were no significant (p>0.05) variations in the parameters when used the drugs in combination (aspirin-clopidogrel) compared with the drugs given alone.

Publication types

  • Comparative Study

MeSH terms

  • Acute Coronary Syndrome / diagnosis
  • Acute Coronary Syndrome / drug therapy*
  • Aspirin / administration & dosage
  • Aspirin / adverse effects*
  • Biomarkers / blood
  • Blood Urea Nitrogen
  • Clopidogrel
  • Creatinine / blood
  • Drug Therapy, Combination
  • Glomerular Filtration Rate / drug effects
  • Humans
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / physiopathology
  • Kidney Diseases / blood
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / physiopathology
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects*
  • Risk Assessment
  • Ticlopidine / administration & dosage
  • Ticlopidine / adverse effects
  • Ticlopidine / analogs & derivatives*
  • Time Factors
  • Treatment Outcome
  • Uric Acid / blood

Substances

  • Biomarkers
  • Platelet Aggregation Inhibitors
  • Uric Acid
  • Clopidogrel
  • Creatinine
  • Ticlopidine
  • Aspirin